Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
143.50
-3.50 (-2.38%)
At close: Feb 14, 2025
34.74%
Market Cap 11.17B
Revenue (ttm) n/a
Net Income (ttm) -731.66M
Shares Out 78.67M
EPS (ttm) -9.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 203,511
Average Volume 354,042
Open 146.50
Previous Close 147.00
Day's Range 141.50 - 146.50
52-Week Range 69.53 - 179.30
Beta -0.07
RSI 51.02
Earnings Date Apr 24, 2025

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.